Developer docs
API playgroundTry for free, no card

Search company profiles

RAFARM S.A

Full company profile

uuid000ji1a

Namestring
RAFARM S.A
Legal namestring
ΡΑΦΑΡΜ ΑΝΩΝΥΜΟΣ ΕΜΠΟΡΙΚΗ ΚΑΙ ΒΙΟΜΗΧΑΝΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ
Websiteurl
rafarmgroup.gr
Company typeenum
Private
Founded yearint
1974
Descriptiontext

RAFARM S.A. is a privately held Greek pharmaceutical manufacturer founded in 1974 and headquartered in Neo Psychiko, Athens, with manufacturing and R&D operations in Paiania, Attica. The company develops, produces, and markets a diversified portfolio of more than 100 pharmaceutical products spanning 7 therapeutic categories—cardiovascular, neurological/urological, hormonal, oncology, respiratory, hematological, and ophthalmic—distributed in Greece through pharmacies and hospitals and exported to more than 60 countries across Europe, the United States, Canada, and globally. Exports represent over 30% of annual net revenue, and RAFARM serves as a contract manufacturing partner to 80 international pharmaceutical companies producing more than 100 products.

The company's technology stack centers on sterile and complex pharmaceutical manufacturing, including a 1,400 sqm sterile production area across five separate GMP-compliant production lines equipped with robotic filling for plastic vials and pre-filled syringes and ultra-modern sterile ophthalmic filling machinery, all under BMS-controlled environments. RAFARM holds 1,100 active pharmaceutical product licenses globally, was the first Greek pharmaceutical company to receive FDA certification for sterile and complex drug development and manufacturing, and currently markets 6 approved products in the United States with 7 more pending. The company invests 10% of annual net revenue into R&D, anchored by a 2,500 sqm ultra-modern R&D Center inaugurated in 2022. Innovation is increasingly routed through the BNS Ophthalmics (BNSO) joint venture with BioNanoSim—which applies the proprietary NTPO nanotechnology platform to novel ophthalmic drug delivery (with pipeline assets including a tacrolimus ophthalmic emulsion holding FDA orphan drug designation)—and through a partnership with Biovista applying AI-driven drug repurposing (COSS platform) in ophthalmology. A 120 million EUR capital program runs through 2027, of which 75 million EUR is allocated to R&D, alongside a Cleveland Clinic collaboration for corneal scar therapy announced in September 2025.

Short descriptiontext

RAFARM S.A. is a privately held Greek pharmaceutical manufacturer founded in 1974 that develops, produces, and distributes more than 100 generic and specialty pharmaceutical products across 7 therapeutic categories, exporting to over 60 countries and serving as contract manufacturer for 80 international pharma companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersAthens, Greece
HQ citystring
Athens
HQ countrystring
Greece
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, generic pharmaceuticals, ophthalmic products, contract manufacturing, sterile injectables
Industry4 codes
PRIMARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Manufacturing
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Product Sales (Domestic)
TypeOne Time License
Description

RAFARM sells its own-developed and manufactured pharmaceutical products through pharmacies and hospitals in Greece. The commercial team maintains a portfolio across 7 therapeutic categories and has launched 30 new products over the past five years.

rafarmgroup.gr
2International Distribution/Co-marketing
TypeOne Time License
Description

RAFARM distributes pharmaceutical products manufactured by international partners in the Greek domestic market through co-marketing and distribution agreements.

rafarmgroup.gr
3Contract Manufacturing
TypeLicensing Royalties
Description

80 pharmaceutical companies worldwide trust RAFARM for the production of more than 100 products. RAFARM develops and manufactures pharmaceutical products for international partners under manufacturing and supply agreements. Exports represent >30% of annual net revenue.

rafarmgroup.gr
4Technology Transfer & Licensing
TypeLicensing Royalties
Description

RAFARM conducts technology transfer projects, bringing products developed by other research teams into its production facilities. This includes pharmaceutical technology transfers covering solid, semi-solid, and liquid dosage forms.

rafarmgroup.gr
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

RAFARM S.A. is a Greek pharmaceutical company that develops, manufactures, and distributes branded generic and value-added pharmaceutical products across 7 therapeutic categories (cardiovascular, nervous system, urological, hormonal, blood/hematological, respiratory, and ophthalmic). The company specializes in sterile and complex ophthalmic and injectable formulations, holds FDA certification for sterile manufacturing, and operates as a contract manufacturer for more than 80 international pharmaceutical companies. Products are sold through pharmacies and hospitals in Greece and exported to over 60 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 100+ pharmaceutical products developed
+5 more records
Product overview1 text field

RAFARM S.A. is a Greek pharmaceutical company and one of the largest in Greece with international presence, celebrating 50 years of operation since 1974. The company operates as a diversified pharmaceutical manufacturer with three main product categories: (1) Proprietary branded generic pharmaceuticals covering 7 therapeutic areas (cardiovascular, nervous system, urological, hormonal, blood/hematological, respiratory, and ophthalmic) marketed under brand names like COMPRELAN, NYZOL, TIAQUEL, XIMLUCI, HUKYNDRA, and statin portfolios; (2) Joint venture subsidiary BNS Ophthalmics (BNSO) developing and producing innovative ophthalmic products using nanotechnology; and (3) Contract manufacturing services for 80+ pharmaceutical companies producing over 400 products. The company has FDA certification for sterile and complex injectable development and manufacturing, with focus on ophthalmic and injectable products including Value Added Medicines (VAM). Products are sold in Greece and exported to 60+ countries, with 6 products currently marketed in the US market.

Product and service6 records
1Generic Pharmaceuticals Portfolio
CategoryGeneric Pharmaceuticals
Description

Over 100 pharmaceutical products across 7 therapeutic categories including cardiovascular, nervous system, urological, hormonal, blood, respiratory, and ophthalmic medications. Over 1,100 active marketing authorizations worldwide. Sold in Greece and exported to 60+ countries.

2Sterile Injectables and Ophthalmic Formulations
CategorySterile Pharmaceutical Manufacturing
Description

Sterile injectable pharmaceutical products including ophthalmic and injectable formulations produced in 1,400 sqm sterile areas across 5 separate production lines with robotic filling equipment for plastic vials, pre-filled syringes, and ultra-modern sterile ophthalmic filling machines.

3Value Added Medicines (VAM)
CategoryValue Added Medicines
Description

Medicines that improve existing drugs through new dosage forms, new indications for active substances, and practical therapeutic regimens leading to better patient compliance, including complex generics and novel pharmaceutical combinations.

4BNS Ophthalmics (BNSO) Nanotechnology Ophthalmic Products
CategoryNanotechnology Ophthalmic Pharmaceuticals
Description

Innovative ophthalmic pharmaceutical products developed using the NTPO nanotechnology platform, including BNSO-1 (Tacrolimus ophthalmic emulsion for chronic anterior uveitis), BNSO-2 (intravitreal steroid with prolonged release for macular edema and AMD), and BNSO-3 (topical dry eye treatment).

5Contract Manufacturing Services
CategoryContract Development and Manufacturing
Description

Contract manufacturing and development services for 80 international pharmaceutical companies, covering sterile ophthalmic and injectable products, co-development of new pharmaceutical products, supply for international markets, and technology transfer projects for solid, semi-solid, and liquid dosage forms.

6Distribution and Co-Marketing in Greek Market
CategoryPharmaceutical Distribution Services
Description

Distribution and co-marketing of pharmaceutical products manufactured by international partners in the Greek domestic market, leveraging RAFARM's commercial reach and regulatory expertise.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-09
Description

Strategic collaboration between RAFARM and Cleveland Clinic for the development of an innovative, non-invasive ophthalmological therapy based on drug repurposing, targeting corneal scar healing - an unmet medical need. RAFARM handles all development process: preclinical trials, clinical studies, formulation optimization, industrial-scale production, and global commercial exploitation.

2Joseph Papa
Strategic tierMinorTypeOthersAnnounced on2023-06-21
Description

Joseph Papa, former Chairman and CEO of Bausch & Lomb, appointed to the Board of Directors of BNS Ophthalmics (BNSO). Brings over 30 years of leadership experience in global pharmaceutical companies for branded and generic drugs across therapeutic areas.

rafarmgroup.gr
3Ari Kellen
Strategic tierMinorTypeOthersAnnounced on2023-06-21
Description

Ari Kellen, experienced healthcare and pharmaceutical executive, appointed to the Board of Directors of BNS Ophthalmics (BNSO). Former Senior Partner at McKinsey & Company, previously led multi-billion dollar P&L at Bausch & Lomb.

rafarmgroup.gr
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-30
Description

Joint venture BNS Ophthalmics (BNSO) established between BNS and RAFARM to develop, produce, and commercialize innovative ophthalmic pharmaceutical products using BNS's proprietary NTPO nanotechnology platform for ophthalmic drug delivery. BNS contributes IP and R&D expertise; RAFARM provides funding and manufacturing infrastructure for commercial-scale production.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

RAFARM has developed significant collaborations with renowned academic institutions in Greece for research and development activities.

6National Centre for Scientific Research 'Democritus'
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with 'Democritus' research institute for scientific research activities.

rafarmgroup.gr
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with NHRF for research and development activities.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

International research collaboration with University of Michigan for pharmaceutical R&D activities.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

International research collaboration with University of Pisa, Italy, for pharmaceutical R&D activities.

10Padagis
Strategic tierMinorTypeStrategic or Co-development Partner
Description

RAFARM co-developed an ophthalmic product with Padagis, which received FDA approval in 2022 for the US market.

rafarmgroup.gr
1180 International Pharmaceutical Companies
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

80 pharmaceutical companies worldwide trust RAFARM for the production of more than 100 pharmaceutical products. RAFARM serves as their manufacturing partner.

rafarmgroup.gr
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

KRKA is a Slovenian-based generic pharmaceutical manufacturer with broad therapeutic area coverage, strong international exports to 70+ countries, and contract manufacturing capabilities. Highly comparable to RAFARM as a Central/Eastern European mid-sized generic pharma with similar export orientation and contract manufacturing model.

TypeDirect peer
Description

Gedeon Richter is a Hungarian-headquartered pharmaceutical company with branded generics, specialty pharmaceuticals (particularly in women's health and CNS), and significant export operations across Europe and CIS. Comparable to RAFARM as an Eastern European pharma player with diversified therapeutic portfolio and international manufacturing footprint.

TypeDirect peer
Description

Stada is a German-headquartered European generics and specialty pharma company with broad therapeutic coverage and significant presence across European markets. Directly comparable to RAFARM in branded generic strategy, European geographic focus, and contract manufacturing services.

4Polpharma
TypeDirect peer
Description

Polpharma is one of the largest Polish pharmaceutical manufacturers, producing generic drugs and APIs with operations across Central/Eastern Europe. Comparable to RAFARM in size, branded generic focus, and EU export orientation from a regional manufacturing base.

TypeDirect peer
Description

Pharmathen is a Greek-headquartered specialty pharmaceutical company focused on generics, complex injectables, and ophthalmic products with strong European export presence. Most direct geographic peer to RAFARM, with overlapping therapeutic areas and similar contract manufacturing/drug development capabilities.

TypeDirect peer
Description

ELPEN is another major Greek pharmaceutical manufacturer producing branded generics across cardiovascular, respiratory, and other therapeutic areas with international presence. Direct domestic peer to RAFARM with similar branded generic strategy and therapeutic portfolio focus.

TypeBroad incumbent
Description

Viatris is a global pharmaceutical major formed from the Mylan-Upjohn merger, offering a broad portfolio of branded and generic medicines across therapeutic areas including ophthalmology. Comparable as a generic/specialty pharma incumbent with overlapping therapeutic categories, though at substantially larger scale than RAFARM.

TypeBroad incumbent
Description

Bausch + Lomb is a global ophthalmology-focused pharmaceutical and medical device company, with leadership in ocular pharmaceuticals including branded ophthalmics. Highly relevant for benchmarking RAFARM's ophthalmology strategy and BNSO pipeline ambition, and notably shares board member overlap via Joseph Papa.

9Padagis
TypeDirect peer
Description

Padagis is a US-based specialty pharmaceutical company focused on extended topical, ophthalmic, and dermatological products. RAFARM has co-developed an FDA-approved ophthalmic product with Padagis (2022 approval), making it both a direct partner and direct peer in ophthalmology specialty generics.

TypeBroad incumbent
Description

Teva is the world's largest generic pharmaceutical manufacturer with extensive specialty pharma operations including branded ophthalmology products. Comparable as a broad incumbent in the same generics and ophthalmology spaces RAFARM serves, though at vastly larger scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RAFARM S.A

Pharmaceutical Manufacturingrafarmgroup.gr

RAFARM S.A. is a privately held Greek pharmaceutical manufacturer founded in 1974 that develops, produces, and distributes more than 100 generic and specialty pharmaceutical products across 7 therapeutic categories, exporting to over 60 countries and serving as contract manufacturer for 80 international pharma companies.

What RAFARM S.A does

RAFARM S.A. is a privately held Greek pharmaceutical manufacturer founded in 1974 and headquartered in Neo Psychiko, Athens, with manufacturing and R&D operations in Paiania, Attica. The company develops, produces, and markets a diversified portfolio of more than 100 pharmaceutical products spanning 7 therapeutic categories—cardiovascular, neurological/urological, hormonal, oncology, respiratory, hematological, and ophthalmic—distributed in Greece through pharmacies and hospitals and exported to more than 60 countries across Europe, the United States, Canada, and globally. Exports represent over 30% of annual net revenue, and RAFARM serves as a contract manufacturing partner to 80 international pharmaceutical companies producing more than 100 products.

The company's technology stack centers on sterile and complex pharmaceutical manufacturing, including a 1,400 sqm sterile production area across five separate GMP-compliant production lines equipped with robotic filling for plastic vials and pre-filled syringes and ultra-modern sterile ophthalmic filling machinery, all under BMS-controlled environments. RAFARM holds 1,100 active pharmaceutical product licenses globally, was the first Greek pharmaceutical company to receive FDA certification for sterile and complex drug development and manufacturing, and currently markets 6 approved products in the United States with 7 more pending. The company invests 10% of annual net revenue into R&D, anchored by a 2,500 sqm ultra-modern R&D Center inaugurated in 2022. Innovation is increasingly routed through the BNS Ophthalmics (BNSO) joint venture with BioNanoSim—which applies the proprietary NTPO nanotechnology platform to novel ophthalmic drug delivery (with pipeline assets including a tacrolimus ophthalmic emulsion holding FDA orphan drug designation)—and through a partnership with Biovista applying AI-driven drug repurposing (COSS platform) in ophthalmology. A 120 million EUR capital program runs through 2027, of which 75 million EUR is allocated to R&D, alongside a Cleveland Clinic collaboration for corneal scar therapy announced in September 2025.

RAFARM S.A firmographics

Firmographics
Name
RAFARM S.A
Legal name
ΡΑΦΑΡΜ ΑΝΩΝΥΜΟΣ ΕΜΠΟΡΙΚΗ ΚΑΙ ΒΙΟΜΗΧΑΝΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ
Website
https://rafarmgroup.gr
Company type
Private
Founded year
1974
Operating status
Operating
Headcount range
251–500 employees
Short description
RAFARM S.A. is a privately held Greek pharmaceutical manufacturer founded in 1974 that develops, produces, and distributes more than 100 generic and specialty pharmaceutical products across 7 therapeutic categories, exporting to over 60 countries and serving as contract manufacturer for 80 international pharma companies.
Ownership category
akta.pro rank

RAFARM S.A industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Pharmaceutical manufacturing
  • Generic pharmaceuticals
  • Ophthalmic products
  • Contract manufacturing
  • Sterile injectables

Where RAFARM S.A is headquartered

Location

Headquarters

HQ city
Athens
HQ country
Greece
HQ region
Europe

Offices3 records

Markets served

RAFARM S.A business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales (Domestic): RAFARM sells its own-developed and manufactured pharmaceutical products through pharmacies and hospitals in Greece. The commercial team maintains a portfolio across 7 therapeutic categories and has launched 30 new products over the past five years.
  2. International Distribution/Co-marketing: RAFARM distributes pharmaceutical products manufactured by international partners in the Greek domestic market through co-marketing and distribution agreements.
  3. Contract Manufacturing: 80 pharmaceutical companies worldwide trust RAFARM for the production of more than 100 products. RAFARM develops and manufactures pharmaceutical products for international partners under manufacturing and supply agreements. Exports represent >30% of annual net revenue.
  4. Technology Transfer & Licensing: RAFARM conducts technology transfer projects, bringing products developed by other research teams into its production facilities. This includes pharmaceutical technology transfers covering solid, semi-solid, and liquid dosage forms.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

RAFARM S.A product offering

Product offering

Core offering

RAFARM S.A. is a Greek pharmaceutical company that develops, manufactures, and distributes branded generic and value-added pharmaceutical products across 7 therapeutic categories (cardiovascular, nervous system, urological, hormonal, blood/hematological, respiratory, and ophthalmic). The company specializes in sterile and complex ophthalmic and injectable formulations, holds FDA certification for sterile manufacturing, and operates as a contract manufacturer for more than 80 international pharmaceutical companies. Products are sold through pharmacies and hospitals in Greece and exported to over 60 countries.

Product overview

RAFARM S.A. is a Greek pharmaceutical company and one of the largest in Greece with international presence, celebrating 50 years of operation since 1974. The company operates as a diversified pharmaceutical manufacturer with three main product categories: (1) Proprietary branded generic pharmaceuticals covering 7 therapeutic areas (cardiovascular, nervous system, urological, hormonal, blood/hematological, respiratory, and ophthalmic) marketed under brand names like COMPRELAN, NYZOL, TIAQUEL, XIMLUCI, HUKYNDRA, and statin portfolios; (2) Joint venture subsidiary BNS Ophthalmics (BNSO) developing and producing innovative ophthalmic products using nanotechnology; and (3) Contract manufacturing services for 80+ pharmaceutical companies producing over 400 products. The company has FDA certification for sterile and complex injectable development and manufacturing, with focus on ophthalmic and injectable products including Value Added Medicines (VAM). Products are sold in Greece and exported to 60+ countries, with 6 products currently marketed in the US market.

Differentiator

Problem solved

Functional benefit

Products and services

  • Generic Pharmaceuticals Portfolio Over 100 pharmaceutical products across 7 therapeutic categories including cardiovascular, nervous system, urological, hormonal, blood, respiratory, and ophthalmic medications. Over 1,100 active marketing authorizations worldwide. Sold in Greece and exported to 60+ countries.
  • Sterile Injectables and Ophthalmic Formulations Sterile injectable pharmaceutical products including ophthalmic and injectable formulations produced in 1,400 sqm sterile areas across 5 separate production lines with robotic filling equipment for plastic vials, pre-filled syringes, and ultra-modern sterile ophthalmic filling machines.
  • Value Added Medicines (VAM) Medicines that improve existing drugs through new dosage forms, new indications for active substances, and practical therapeutic regimens leading to better patient compliance, including complex generics and novel pharmaceutical combinations.
  • BNS Ophthalmics (BNSO) Nanotechnology Ophthalmic Products Innovative ophthalmic pharmaceutical products developed using the NTPO nanotechnology platform, including BNSO-1 (Tacrolimus ophthalmic emulsion for chronic anterior uveitis), BNSO-2 (intravitreal steroid with prolonged release for macular edema and AMD), and BNSO-3 (topical dry eye treatment).
  • Contract Manufacturing Services Contract manufacturing and development services for 80 international pharmaceutical companies, covering sterile ophthalmic and injectable products, co-development of new pharmaceutical products, supply for international markets, and technology transfer projects for solid, semi-solid, and liquid dosage forms.
  • Distribution and Co-Marketing in Greek Market Distribution and co-marketing of pharmaceutical products manufactured by international partners in the Greek domestic market, leveraging RAFARM's commercial reach and regulatory expertise.

Quantifiable outcome

  • 100+ pharmaceutical products developed
  • +5 more outcomes

Companies that use RAFARM S.A

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

RAFARM S.A technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

RAFARM S.A partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • Cleveland CliniccoreStrategic or Co-development Partner · 9 September 2025Strategic collaboration between RAFARM and Cleveland Clinic for the development of an innovative, non-invasive ophthalmological therapy based on drug repurposing, targeting corneal scar healing - an unmet medical need. RAFARM handles all development process: preclinical trials, clinical studies, formulation optimization, industrial-scale production, and global commercial exploitation.
  • Joseph PapaminorOthers · 21 June 2023Joseph Papa, former Chairman and CEO of Bausch & Lomb, appointed to the Board of Directors of BNS Ophthalmics (BNSO). Brings over 30 years of leadership experience in global pharmaceutical companies for branded and generic drugs across therapeutic areas.
  • Ari KellenminorOthers · 21 June 2023Ari Kellen, experienced healthcare and pharmaceutical executive, appointed to the Board of Directors of BNS Ophthalmics (BNSO). Former Senior Partner at McKinsey & Company, previously led multi-billion dollar P&L at Bausch & Lomb.
  • BioNanoSim (BNS)coreStrategic or Co-development Partner · 30 May 2023Joint venture BNS Ophthalmics (BNSO) established between BNS and RAFARM to develop, produce, and commercialize innovative ophthalmic pharmaceutical products using BNS's proprietary NTPO nanotechnology platform for ophthalmic drug delivery. BNS contributes IP and R&D expertise; RAFARM provides funding and manufacturing infrastructure for commercial-scale production.
  • University of Athens, Thessaloniki, Patras, Crete, IoanninaminorStrategic or Co-development PartnerRAFARM has developed significant collaborations with renowned academic institutions in Greece for research and development activities.
  • National Centre for Scientific Research 'Democritus'minorStrategic or Co-development PartnerCollaboration with 'Democritus' research institute for scientific research activities.
  • National Hellenic Research Foundation (NHRF)minorStrategic or Co-development PartnerCollaboration with NHRF for research and development activities.
  • University of Michigan, USAminorStrategic or Co-development PartnerInternational research collaboration with University of Michigan for pharmaceutical R&D activities.
  • University of Pisa, ItalyminorStrategic or Co-development PartnerInternational research collaboration with University of Pisa, Italy, for pharmaceutical R&D activities.
  • PadagisminorStrategic or Co-development PartnerRAFARM co-developed an ophthalmic product with Padagis, which received FDA approval in 2022 for the US market.
  • 80 International Pharmaceutical CompaniesminorChannel Partner/ Reseller/ Distributor80 pharmaceutical companies worldwide trust RAFARM for the production of more than 100 pharmaceutical products. RAFARM serves as their manufacturing partner.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

RAFARM S.A competitors and assessment

Company assessment

Direct peers

  • KRKA: KRKA is a Slovenian-based generic pharmaceutical manufacturer with broad therapeutic area coverage, strong international exports to 70+ countries, and contract manufacturing capabilities. Highly comparable to RAFARM as a Central/Eastern European mid-sized generic pharma with similar export orientation and contract manufacturing model.
  • Gedeon Richter: Gedeon Richter is a Hungarian-headquartered pharmaceutical company with branded generics, specialty pharmaceuticals (particularly in women's health and CNS), and significant export operations across Europe and CIS. Comparable to RAFARM as an Eastern European pharma player with diversified therapeutic portfolio and international manufacturing footprint.
  • Stada Arzneimittel: Stada is a German-headquartered European generics and specialty pharma company with broad therapeutic coverage and significant presence across European markets. Directly comparable to RAFARM in branded generic strategy, European geographic focus, and contract manufacturing services.
  • Polpharma: Polpharma is one of the largest Polish pharmaceutical manufacturers, producing generic drugs and APIs with operations across Central/Eastern Europe. Comparable to RAFARM in size, branded generic focus, and EU export orientation from a regional manufacturing base.
  • Pharmathen: Pharmathen is a Greek-headquartered specialty pharmaceutical company focused on generics, complex injectables, and ophthalmic products with strong European export presence. Most direct geographic peer to RAFARM, with overlapping therapeutic areas and similar contract manufacturing/drug development capabilities.
  • ELPEN Pharmaceutical: ELPEN is another major Greek pharmaceutical manufacturer producing branded generics across cardiovascular, respiratory, and other therapeutic areas with international presence. Direct domestic peer to RAFARM with similar branded generic strategy and therapeutic portfolio focus.
  • Padagis: Padagis is a US-based specialty pharmaceutical company focused on extended topical, ophthalmic, and dermatological products. RAFARM has co-developed an FDA-approved ophthalmic product with Padagis (2022 approval), making it both a direct partner and direct peer in ophthalmology specialty generics.

Broad incumbents

  • Viatris: Viatris is a global pharmaceutical major formed from the Mylan-Upjohn merger, offering a broad portfolio of branded and generic medicines across therapeutic areas including ophthalmology. Comparable as a generic/specialty pharma incumbent with overlapping therapeutic categories, though at substantially larger scale than RAFARM.
  • Bausch + Lomb: Bausch + Lomb is a global ophthalmology-focused pharmaceutical and medical device company, with leadership in ocular pharmaceuticals including branded ophthalmics. Highly relevant for benchmarking RAFARM's ophthalmology strategy and BNSO pipeline ambition, and notably shares board member overlap via Joseph Papa.
  • Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with extensive specialty pharma operations including branded ophthalmology products. Comparable as a broad incumbent in the same generics and ophthalmology spaces RAFARM serves, though at vastly larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

RAFARM S.A social profiles

Digital presence

RAFARM S.A compliance and trust

Trust signal

Compliance2 records

RAFARM S.A financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RAFARM S.A leadership team

Management profile

Number of profiles

Profiles10 records

RAFARM S.A subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

RAFARM S.A funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RAFARM S.A M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RAFARM S.A

What does RAFARM S.A do?

RAFARM S.A. is a Greek pharmaceutical company that develops, manufactures, and distributes branded generic and value-added pharmaceutical products across 7 therapeutic categories (cardiovascular, nervous system, urological, hormonal, blood/hematological, respiratory, and ophthalmic). The company specializes in sterile and complex ophthalmic and injectable formulations, holds FDA certification for sterile manufacturing, and operates as a contract manufacturer for more than 80 international pharmaceutical companies. Products are sold through pharmacies and hospitals in Greece and exported to over 60 countries.

Is RAFARM S.A a public or private company?

RAFARM S.A is a private company. It is classified as family owned and is currently operating.

When was RAFARM S.A founded?

RAFARM S.A was founded in 1974. It employs 251 to 500 people.

Where is RAFARM S.A based?

RAFARM S.A is headquartered in Athens, Greece, in the Europe region.

How does RAFARM S.A make money?

Four revenue lines are on record. Pharmaceutical Product Sales (Domestic) is the primary driver. The others are international Distribution/Co-marketing, contract Manufacturing and technology Transfer & Licensing.

Who are RAFARM S.A's main competitors?

Direct peers on record are KRKA, Gedeon Richter, Stada Arzneimittel, Polpharma, Pharmathen, ELPEN Pharmaceutical and Padagis. Broad incumbents are Viatris, Bausch + Lomb and Teva Pharmaceutical Industries.

Does RAFARM S.A have an API?

No public API is recorded for RAFARM S.A.

What industry is RAFARM S.A in?

RAFARM S.A's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAA, Small-Molecule Generics (Branded/Unbranded), with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals